New drug for people with active lupus
Part of Immune system & allergy, Skin clinical trials.
This trial is testing a new investigational drug called QLS4131 in people with systemic lupus erythematosus (SLE), an autoimmune disease where the immune system attacks healthy tissues. The goal is to see if it is safe and effective in reducing disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with systemic lupus erythematosus (SLE) for at least 12 weeks.
- Your lupus is active, as shown by a score of 8 or higher on a standard activity scale, or 6 or higher if you also have low complement or certain antibodies.
- You are currently taking at least one standard lupus treatment, like steroids (up to 40 mg of prednisone daily), an antimalarial (e.g., hydroxychloroquine), or an immunosuppressant (e.g., azathioprine, mycophenolate, methotrexate).
- You do not have severe lupus complications (like active kidney disease or nervous system issues), another autoimmune disease, poorly controlled blood pressure or diabetes, a recent cancer history, or a history of organ transplantation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
This study tests a new injection (QLS2404) in two groups: healthy volunteers and people with certain autoimmune diseases like lupus or Sjögren's syndrome. The goal is to see if the treatment is safe and how it affects the body, which could lead to new options for managing these conditions.
This trial tests an experimental oral tablet for people with systemic lupus erythematosus. It aims to see if the new medicine can help reduce lupus symptoms when added to your current standard treatment. Participants will receive the study drug and be monitored closely.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
This study tests an experimental daily pill (BI 3000202) for people with active lupus (SLE) to see if it can reduce disease activity. It compares different doses against a placebo, and you must already be on stable lupus background treatment.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.